http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-089945-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cc25c555cd0514a354d64df675e0be15 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4355 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D407-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436 |
| filingDate | 2013-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9061c1b87c83c394d15b78cb58f66dce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03a366abb3581a62d41b9c4c852993bf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5168895e47ce4dec0675d49a5809208 |
| publicationDate | 2014-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-089945-A1 |
| titleOfInvention | FURO DERIVATIVES [3,2-B] AND HAVE [3,2-B] PIRIDINE AS MODULATORS OF TBK1 AND IKKe |
| abstract | The compounds of the formula (1) wherein X denotes O or S; R¹ denotes O (CYY) ₙHet¹, NY (CYY) ₙHet¹, O (CYY) ₙCyc or NY (CYY) ₙCyc; R² denotes H, Hal, A, OY, NYY, O (CYY) ₘNYY, O (CYY) ₙHet², NY (CYY) ₘNYY, NY (CYY) ₙHet², Ar or Het²; Het¹ denotes dihydropyrrolyl, pyrrolidinyl, tetrahidroimida-zolilo, dihydropyrazolyl, tetrahidropirazolilo, tetrahydropyranyl, dihydropyridyl, tetrahydropyridyl, piperidinyl morpholinyl, hexahydropyridazinyl, hexahydropyrimidinyl [1,3] dioxolanyl-oxa-6 2-azaspiro [3.3] heptanyl, azepanyl, diazepanyl, tetrahydrofuranyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, chromanyl or piperazinyl, each of which is unsubstituted or mono- or disubstituted Hal, CN, A, COOA, OY, S (O) ₙA, S (O) ₙAr and / u = O (carbonyl oxygen); Het² denotes a saturated, unsaturated or aromatic mono-, bi- or tricyclic heterocycle having 1 to 4 atoms of N, O and / or S, which may not be substituted or which may be mono-, di-, tri-, tetra - or penta-substituted with Hal, A, (CYY) ₚ-OY, - (CYY) ₚ-NYY, (CYY) ₚ-Het¹, NO₂, CN, (CYY) ₚ-COOY, CO-NYY, NY-COA , NY-SO₂A, SO₂-NYY, S (O) ₙA, -CO-Het¹, O (CYY) ₚ-NYY, -O (CYY) ₚ-Het¹, NH-COOA, NH-CO-NYY, NH-COO - (CYY) ₚ-NYY, NH-COO- (CYY) ₚ-Het¹, NH-CO-NH- (CYY) ₚ-NYY, NH-CO-NH (CYY) ₚ-Het¹, OCO-NH- (CYY ) ₚ-NYY, OCO-NH- (CYY) ₚ-Het¹, CHO, COA, = S, = NY and / u = O; Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted with Hal, A, (CYY) ₚ-OY, (CYY) ₚ-NYY, (CYY) ₚ- Het¹, NO₂, CN, (CYY) ₚ-COOY, CO (CYY) ₚNH₂, CO-NYA, CONY (CYY) ₘNYCOOA, NY-COA, NY-SO₂A, SO₂-NYY, S (O) ₙA, CO-Het¹ , O (CYY) ₚ-NYY, O (CYY) ₚ-Het¹, NH-COOA, NH-CO-NYY, NH-COO- (CYY) ₚ-NYY, NH-COO- (CYY) ₚ-Het¹, NH -CO-NH- (CYY) ₚ-NYY, NH-CO-NH (CYY) ₚ-Het¹, OCO-NH- (CYY) NY-NYY, OCO-NH- (CYY) ₚ-Het¹, CHO, CONY ( CYY) ₚHet¹, CONH (CYY) ₚNHCOA and / or COA; Y denotes H or C₁₋₄ alkyl; A denotes unbranched or branched C₁₋₁₀ alkyl, wherein 1-7 H atoms can be replaced by F and / or Cl and / or where one or two non-adjacent groups CH and / or CH₂ can be replaced by O and / or N; Cyc denotes C₃₋₇ cycloalkyl, which is unsubstituted or which is monosubstituted with Hal, CN or A; Hal denotes F, CI. Br or I; n denotes 0, 1, or 2; m denotes 1, 2 or 3; p denotes 0.1, 2, 3 or 4; and its pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures in all proportions. They are inhibitors of TBK1 and lKKe and can be used, inter alia, for the treatment of cancer and inflammatory diseases. |
| priorityDate | 2012-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 60.